Lv11
8 积分 2023-06-15 加入
Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
2小时前
已完结
CT-based radiogenomics of intrahepatic cholangiocarcinoma
6个月前
已完结
Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma
1年前
已完结
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
1年前
已完结
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
1年前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1年前
已完结
Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up
1年前
已完结
Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma
1年前
已完结
First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
1年前
已完结
An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study
1年前
已完结
皖公网安备34019202002308
